Duaklir 340micrograms / dose / 12micrograms / dose Genuair (AstraZeneca UK Ltd) 60 dose

Type Dry powder inhaler (DPI)
Medicine Aclidinium bromide 396micrograms/dose + Formoterol 11.8micrograms/dose
Activation mechanism Breath actuated
Dose counter Has dose counter
Price £32.50 / 30 days
(based on 2 puffs / day)
Licences
  • COPD Licence

Training material

Pathways

The use of each medicine included in Right Breathe has been considered in relation to international, national, and regional prescribing pathways. The pathway points at which this medicine is considered a viable prescribing option are included below. If you wish to view the entire pathway, click on its heading, from where you can also access all the prescribing options for each pathway and each pathway point.

Prescribing

Detailed prescribing information is provided below. This content has not been generated by the RightBreathe team, but has been integrated from a 3rd party solution: Multilex (provided by FirstDataBank). Use of this prescribing content is subject to the FirstDataBank disclaimer, which is set out in the "About" section of RightBreathe.

As RightBreathe is a bespoke decision support tool, it covers each and every individual known inhaler option on the UK market to a high level of specificity. Multilex, as a more general resource, does not offer the same level of specificity. There are therefore a small number of medicines for which there are discrepancies between RightBreathe and Multilex content, most notably in relation to licensed particulars and associated licensed doses.

Given the high level of specificity the RightBreathe team work to, details of the individual inhaler licence are most likely to be summarised accurately in the content provided at the top of this page, rather than in the Multilex content below. Where there is ambiguity, users may also wish to refer to individual summaries of product characteristics prior to prescribing.

Dosing

Chronic obstructive pulmonary disease

Type Age Range Dose Licensed
Maintenance From 18 years 1 actuation - TWICE a DAY - inhalation - using a metered dose device

Safety Advice Warnings

Adverse effects (report/action)

  • May cause hypokalaemia
  • Prolonged treatment may lead to dental caries
  • Risk of narrow angle glaucoma

Advice on possible excipients

  • Contains lactose

Discontinue due to test or exam

  • Discontinue if paradoxical bronchospasm occurs

Patient Counselling

  • Advise ability to drive/operate machinery may be affected by side effects
  • Advise patient not to exceed stated dose
  • Advise patient to seek medical advice if treatment is ineffective
  • Ensure patient has a fast acting bronchodilator available

Pre-treatment points to consider

  • Correct electrolyte disorders before treatment

Recommended monitoring

  • Check patient is using correct inhaler technique
  • Consider monitoring ECG in patients at risk of QT prolongation
  • Monitor blood glucose closely in patients with diabetes mellitus
  • Monitor serum K+ in patients on high dose steroids/xanthines/diuretics
  • Monitor serum electrolytes

Safety/advice in other condition

  • Not suitable for acute treatment of asthma

Drug Interactions

With Risk Severity
ATOMOXETINE May increase risk of cardiac effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
BETA BLOCKERS effect antagonised by Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
BETA BLOCKERS AND THIAZIDE DIURETICS effect antagonised by Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
DOMPERIDONE Predisposing factors may increase risk of arrhythmias Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
LEVACETYLMETHADOL Hypokalaemia with high dose beta-agonist increases risk of arrhythmias Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
SOTALOL Effect antagonised/ predisposing factors increase risk of arrhythmias Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
AJMALINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
AMIODARONE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ANAGRELIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ARSENIC TRIOXIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ARTEMETHER AND LUMEFANTRINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ASTEMIZOLE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
AZITHROMYCIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CHLOROQUINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CILOSTAZOL Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CIPROFLOXACIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CITALOPRAM / ESCITALOPRAM Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CLARITHROMYCIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
COCAINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
DELAMANID Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
DISOPYRAMIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
DRONEDARONE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
DROPERIDOL Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ERYTHROMYCIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ETELCALCETIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
FLECAINIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
FLUCONAZOLE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
HALOFANTRINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
HALOPERIDOL Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
HYDROXYZINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
INOTUZUMAB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
LEVOFLOXACIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
METHADONE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
MOXIFLOXACIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ONDANSETRON Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
OSIMERTINIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
OXALIPLATIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PAPAVERINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PENTAMIDINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PHENOTHIAZINES (QT 1) Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PIMOZIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PROPOFOL Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
QUINIDINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
RETIGABINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
SEVOFLURANE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
SODIUM STIBOGLUCONATE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
SULPIRIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
TERLIPRESSIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
VANDETANIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ACE INHIBITORS WITH THIAZIDE DIURETICS Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
ACETAZOLAMIDE Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
ANGIOTENSIN II INHIBITORS AND THIAZIDE DIURETICS Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
BETA BLOCKER EYE DROPS effect antagonised by Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
CORTICOSTEROIDS Increased risk of hypokalaemia with high doses of both drugs Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
LOOP DIURETICS Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
THEOPHYLLINE Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
THIAZIDE DIURETICS Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.

Precautions

  • Benign prostatic hyperplasia
  • Bladder outflow obstruction
  • Breastfeeding
  • Cardiac arrhythmias
  • Diabetes mellitus
  • Electrolyte imbalance
  • Family history of long QT syndrome
  • Glucose-galactose malabsorption syndrome
  • History of torsade de pointes
  • Hypertension
  • Hypoxia
  • Lactose intolerance
  • Narrow angle glaucoma
  • New York Heart Association class III failure
  • New York Heart Association class IV failure
  • Phaeochromocytoma
  • Pregnancy
  • Seizures
  • Severe cardiovascular disorder
  • Thyrotoxicosis
  • Unstable angina
  • Urinary retention
  • Within 6 months of a myocardial infarction

Contraindications

  • Children under 18 years
  • Galactosaemia
  • Long QT syndrome
  • Torsade de pointes

Side Effects

  • Agitation
  • Anaphylactic reaction
  • Angina pectoris
  • Angioedema
  • Anxiety
  • Blurred vision
  • Bronchospasm (paradoxical)
  • Cough
  • Creatine phosphokinase increased
  • Diarrhoea
  • Dizziness
  • Dry mouth
  • Dysgeusia
  • Dysphonia
  • Headache
  • Hyperglycaemia
  • Hypersensitivity reactions
  • Hypokalaemia
  • Increased blood pressure
  • Insomnia
  • Muscle spasm
  • Myalgia
  • Nasopharyngitis
  • Nausea
  • Palpitations
  • Peripheral oedema
  • Prolongation of QT interval
  • Pruritus
  • Rash
  • Sinusitis
  • Stomatitis
  • Tachycardia
  • Throat irritation
  • Tooth abscess
  • Tremor
  • Urinary retention
  • Urinary tract infections